CEACAM5 and neoplasm: With respect to anti-tumor activity, both CEA-28ζ-K and CEA-28ζ-I1 CAR T cells evinced robust elimination of BxPC-3 cells in the first two rounds of cancer cell challenge while cancer cell elimination declined in round three.